SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is at the center of intense market speculation as investors await quarterly results, with the community deeply divided between those betting on a massive earnings beat to sustain the AI rally and those fearing a classic sell-the-news event. The conversation is heavily focused on whether the company can continue to justify its high valuation through aggressive data center growth and AI infrastructure demand, with traders closely monitoring the broader impact on the semiconductor sector and key tech indices.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the FDA's acceptance of their supplemental BLA for ANKTIVA, a move that potentially expands the drug's label to cover the larger papillary-only bladder cancer population. The community is actively discussing the stock's long-term potential, debating the implications of the January 2027 PDUFA date, and expressing strong conviction in the company's platform despite ongoing volatility and short-selling pressure.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as investors weigh strong operational milestones like expanded battery-swap infrastructure and institutional backing against persistent volatility and skepticism regarding its market valuation. The community is actively debating the stock's future, split between those focusing on long-term growth potential and those frustrated by mechanical price suppression and historical underperformance.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is experiencing intense volatility ahead of its upcoming earnings report, with the community polarized between those betting on a strong post-earnings rally due to resilient demand and those fearing a deep correction. Investors are actively debating the impact of tariff uncertainty and potential tariff refunds, while many retail participants see the current price action as a manipulative shakeout designed to force weak hands out before a projected recovery.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as investors weigh significant AI and cloud growth against earnings concerns, while the stock sees heavy volatility driven by speculation around high-level diplomatic talks and potential tariff shifts between the U.S. and China. The community remains deeply divided, with bulls betting on a long-term AI-driven re-rating and short-term catalyst plays, while bears continue to highlight valuation traps and historical price underperformance.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending as traders react to a strong quarterly earnings report that featured a double beat on earnings and revenue alongside raised full-year guidance. The community is actively debating the company's high valuation relative to its rapid store growth and successful marketing strategy, while bulls celebrate the stock's significant price momentum.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending as investors respond to a wave of analyst upgrades and positive sentiment surrounding the company's AI-integrated workflow orchestration. The stock is seeing significant interest from the community as market participants debate whether this momentum signals a broader sector rotation into enterprise software or a short-term rebound.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is facing intense selling pressure as it hits new 52-week lows, driven by investor concerns over discretionary consumer spending, leadership transitions, and high-margin volatility. While the community remains divided, discussions focus on whether the stock is significantly oversold and providing a long-term entry opportunity or if it is currently caught in a cycle of institutional manipulation and broader economic headwinds.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is experiencing a surge in investor interest and bullish momentum following optimistic commentary from the CEO regarding the survival data of its REGAL Phase 3 clinical trial. The community is actively discussing the potential for an imminent short squeeze and institutional accumulation as they wait for the 80th trial event, with many viewing the company's immunotherapy platform as a major, de-risked candidate for future valuation growth.

SPX6900 is an advanced blockchain cryptography token coin capable of limitless possibilities and scientific utilization.

SPX6900

The SPX6900 (SPX) community remains highly active and committed to a long-term 'DCA' strategy, positioning the token as a cultural movement and a decentralized alternative to traditional financial structures. Investors are intensely focused on its potential for outsized growth as a 'pure belief asset,' with ongoing discussions highlighting the token's availability on major exchanges and its perceived role as a primary vehicle for liquidity in the broader crypto ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

US Reclassifies Weed: Can Cannabis ETFs Give Your Portfolio a New High? 

 Medical marijuana's US reclassification revives cannabis ETFs like WEED, with tax relief and reform hopes fueling sharp gains across the sector.

AdvisorShares Issues Statement on Finalization of Federal Cannabis Rescheduling

AdvisorShares Issues Statement on Finalization of Federal Cannabis Rescheduling AdvisorShares Issues Statement on Finalization of Federal Cannabis Rescheduling PR Newswire BETHESDA, Md., April 23...

<ul class="summary-bullets"><li>Roth Capital upgraded its rating on TRLY to ‘Overweight,’ while Alliance Global maintained ‘neutral.’</li><li>Last year, the U.S. tightened rules on hemp-derived THC products, and now various states are also restricting or banning those products.</li><li>On Wednesday, Tirlay reported fiscal third-quarter results.</li></ul>Tilray Brands, Inc.’s third-quarter report drew a mixed reaction from Wall Street, as analysts balanced improving business fundamentals against looming regulatory shifts that could disrupt the marijuana industry.TLRY shares declined 1.5% in early premarket trading on Thursday, following a 5% dip the previous session.Alliance Global lowered its price target on TLRY to $7 from $9 (14% upside projection), while keeping a ‘Neutral’ rating, citing uncertainty over hemp restrictions.In November, the U.S. government tightened hemp regulations by capping&nbsp;total levels of tetrahydrocannabinol (THC) — the primary psychoactive component in cannabis that produces a “high”&nbsp;— at 0.3%, while also restricting products such as Delta-8, effectively curbing many intoxicating hemp items, including edibles, vapes, and beverages. Last month, Texas added further pressure by banning smokable hemp products and raising licensing fees, with more states expected to follow suit.On the other hand, Roth Capital upgraded its rating on TLRY to ‘Buy’ from ‘Neutral’ with an unchanged $10 price target.&nbsp; The research firm praised Tilray’s upbeat results, particularly the Canadian and international segments. Tilray shares are back at July 2025 levels, but the fundamental outlook has improved, and the potential for regulatory change is greater, the firm added.<h2 class="st-heading-2">Q3 Results Recap</h2>Revenue rose 19% to $206.7 million, helped by sharp growth in international sales, and came in higher than the $201.3 million expectation. Net loss narrowed significantly to $25.2 million from $793.5 million a year earlier. On an adjusted basis, loss per share of $0.24 missed the analyst target of $0.14.Tilray said international sales increased 73%, while its Tilray Pharma segment grew 34%. The company reaffirmed its outlook for fiscal 2026 core earnings of $62 million to $72 million.<h2 class="st-heading-2">Retail, Analyst View On TLRY</h2>On Stocktwits, retail sentiment for TLRY shifted from ‘bullish’ to ‘bearish’ following the results.&nbsp;“$TLRY Slow and steady wins the race. It sure ain't Nvidia, but I'll take it. Slight dip in margins, amid a sea of price compression. Revenue beat, and earnings meet. Not bad,”&nbsp;<a href="https://stocktwits.com/davidjbenz/message/649151732">said</a> a user.To be sure, traders are trading stock in anticipation of the U.S. potentially classifying marijuana as a Schedule III (S3) drug, indicating that it has a lesser potential for abuse and is allowed for use in specific medical treatment.Marijuana remains a Schedule I drug under federal law — the same category as heroin and LSD – a classification reserved for substances deemed to have high abuse potential and no accepted medical use. Weed stocks, including TLRY, rallied sharply in December after President Donald Trump announced&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-moves-a-step-closer-to-reclassifying-marijuana-as-a-less-dangerous-drug-a-breakout-moment-for-weed-industry/cLICa8WREFB">plans to reclassify</a>. It hasn’t happened yet.“Even without S3 record results, why are people so sad,”&nbsp;<a href="https://stocktwits.com/Tradefun1979/message/649157581">said</a> another Stocktwits user. “S3 is bonus but currently co. Is not doing bad, actually stellar results. I am buying and will hold Long term, very cheap now.”Meanwhile, Wall Street is in a wait-and-watch mode. Currently, seven out of 10 analysts have a ‘Hold’ rating on the stock, two rate it ‘Buy’, and one&nbsp;rates it ‘Strong Sell’, per Koyfin. Their average price target of $11.14 implies an over 80% upside from the stock’s last close.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, a Tilray Brands logo is seen displayed on a smartphone and in the background.

TLRY Stock Drops Premarket: Why Analysts Are Mixed Despite Upbeat Q3 Report 

Tirlay Brands shares have declined 33% year to date.

Equity

Tirlay Brands shares have declined 33% year to date.


<ul class="summary-bullets"><li>The deal includes an initial five-year term and may automatically renew for another five years if performance targets are met.</li><li>The licensing agreement is expected to deliver immediate scale and revenue as soon as it goes into effect.&nbsp;</li><li>The expanded portfolio is expected to strengthen Tilray’s distributor relationships and broaden national chain offerings.</li></ul>Tilray Brands, Inc. (TLRY) on Wednesday announced that it has secured exclusive rights to brew, market, and distribute several Carlsberg beer brands across the U.S. beginning in 2027.Tilray is a diversified global consumer goods company and the fourth-largest craft beer brewer in the U.S.<h2 class="st-heading-2">Expanding U.S. Beer Presence</h2>The multi-year licensing agreement with the Danish brewing giant will allow Tilray to produce and distribute Carlsberg, Carlsberg Elephant, 1664, and Kronenbourg 1664 Blanc beers in all U.S. channels starting Jan. 1, 2027.&nbsp;The deal includes an initial five-year term and may automatically renew for another five years if performance targets are met. Tilray will use its brewing facilities, sales teams, and commercial networks to locally make and grow the market reach of these imported beers.&nbsp;Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/TLRY">Tilray Brands’ stock&nbsp;</a>traded over 4% higher by Wednesday mid-morning.&nbsp;<h2 class="st-heading-2">Strategic Benefits For Tilray</h2>The licensing agreement is expected to deliver immediate scale and revenue as soon as it goes into effect.&nbsp;<blockquote>“By combining Carlsberg’s iconic global brands and proven brewing heritage with Tilray Beverages’ U.S. operational scale, quality standards, and national commercial team, we are well positioned to expand Carlsberg’s presence in the premium European segment and drive long-term growth in the U.S. beer market.”-Irwin D. Simon, Chairman and CEO, Tilray</blockquote>This expanded portfolio may help strengthen Tilray’s distributor relationships, broaden national chain offerings, and enhance its standing in the U.S. beverage category.<h2 class="st-heading-2">How Did Stocktwits Users React?&nbsp;</h2>On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume changed to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_18_112750_png_7df23c56bf.webp" alt="TLRY’s Sentiment Meter and Message Volume as of 11:20 a.m. ET on Feb. 18, 2026 | Source: Stocktwits" width="935" height="110"><figcaption>TLRY’s Sentiment Meter and Message Volume as of 11:20 a.m. ET on Feb. 18, 2026 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user lauded the partnership.<stembedurl>https://stocktwits.com/Alexsolstice/message/645225129</stembedurl>&nbsp;TLRY stock has declined by over 12% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-stock-fda-accepts-revised-flu-vaccine-application-for-review/cZR0MwoR4v1">Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tilray To Produce And Distribute Carlsberg Beer Brands In US – Stock Gains 4%

The multi-year licensing agreement with the Danish brewing giant will allow Tilray to produce and distribute several Carlsberg beer brands in all U.S. channels starting Jan. 1, 2027. 

<ul class="summary-bullets"><li>Tilray’s Q2 revenue rose 3% to $217.5 million, beating estimates of $211.5 million, according to Fiscal.ai data</li><li>The management reaffirmed its fiscal 2026 adjusted EBITDA outlook of $62 million to $72 million.</li><li>Tilray is currently operating at an annualized run rate of about $150 million, CEO Irwin D. Simon told analysts on a call on Thursday.</li></ul>Tilray Brands (TLRY) stock gave up most of its early gains to trade about 2.5% higher on Friday after Alliance Global slashed its price target on the stock, pointing to limited visibility into the company’s long-term sales trajectory and cash flow following its second-quarter (Q2) fiscal 2026 results.Analyst Aaron Grey reduced Tilray’s target price to $10 from $20 while maintaining a ‘Neutral’ rating. He said the quarter came in largely in line at the consolidated level, with “some strengths offsetting some weaknesses,” but the firm stayed on the sidelines, looking for clearer insight into the company’s sales and cash flow outlook.<h2 class="st-heading-2">Q2 Print</h2>Tilray’s second-quarter (Q2) revenue rose 3% to $217.5 million, beating estimates of $211.5 million, according to Fiscal.ai data. The revenue increase was driven by a 36% jump in international medical cannabis sales. Net loss narrowed to $43.5 million from $85.3 million a year earlier.Operating cash flow remained negative, though it narrowed to $8.5 million compared to $40.7 million last year. The firm’s management reaffirmed its fiscal 2026 adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) outlook of $62 million to $72 million, citing long-term opportunities tied to U.S. cannabis rescheduling and medical expansion.Chairman and CEO Irwin D. Simon told analysts on a call on Thursday that Tilray is currently operating at an annualized run rate of about $150 million, driven mainly by international markets. Simon also added that Europe, particularly Germany, the U.K., and Poland, represents a significant growth opportunity.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday gains, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/TLRY">TLRY</a> remained in the ‘bearish’ territory over the past 24 hours.<figure class="image"><img src="https://news.stocktwits-cdn.com/TLRY_jpg_463814541d.webp" alt="TLRY.jpg" width="922" height="96"><figcaption>&nbsp;</figcaption></figure>However, some users were bullish, with one highlighting Tilray’s strong results.<stembedurl>https://stocktwits.com/Mlitton13/message/641317326</stembedurl>The stock has declined 24% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-oklo-stock-surged-premarket-today-meta-deal/cmU2fX3R4dI">OKLO Stock Surged 20% In Premarket Today – What’s The Meta Agreement About?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

TLRY Stock In Focus After Alliance Global Halves Price Target

Alliance Global cut TLRY’s target price to $10 from $20, citing limited visibility into the company’s long-term sales trajectory and cash flow.

Cannabis ETFs Soar Double-Digits on Friday: Here's Why

Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.

Cannabis plants grow in the greenhouse at Vireo Health's medical marijuana cultivation facility, August 19, 2016 in Johnstown, New York. (Photo by Drew Angerer/Getty Images)

Trump Moves A Step Closer To Reclassifying Marijuana As A Less Dangerous Drug — A Breakout Moment For Weed Industry?

The cannabis industry is enjoying renewed momentum under Trump, whose administration has adopted a notably more accommodative approach toward the drug and its related products.

<ul class="summary-bullets"><li>Bloomberg reported that the Centers for Medicare &amp; Medicaid Services (CMS), which runs the Medicare program, is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;</li><li>MSOS and YOLO, two key cannabis sector-focused funds, gained 3.4% and 2.7%, respectively.</li><li>The Trump administration seems to be backing cannabis as an industry, following its previous comments regarding CBD and reclassifying marijuana.</li></ul>Cannabis&nbsp;stocks advanced on Wednesday following a report speculating that certain U.S Medicare patients could soon be eligible to receive coverage for CBD under a new initiative.CBD, or cannabidiol, is a compound found in cannabis and used to treat sleep disorders, anxiety, pain, and inflammation. Some research suggests it may also treat cancer symptoms. The drug is sold as gummies, pet treats, and skincare supplements.<h2 class="st-heading-2">Cannabis Stocks Rally</h2>Tilray Brands’ shares rose 4.8%, while the over-the-counter stocks of Curaleaf Holdings, Trulieve Cannabis, and Green Thumb Industries gained between 2% to 5.6%. Shares of Innovative Industrial Properties, a real estate investment trust (REIT) that buys and leases specialized cannabis cultivation facilities, rose 1.1%.On Stocktwits, the retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/TLRY">TLRY</a> shifted to ‘extremely bullish’ from ‘bullish,’ while that for&nbsp;<a href="https://stocktwits.com/symbol/CURLF">CURLF</a> shifted to ‘bullish’ from ‘neutral.’ The sentiment was ‘bullish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">GTBIF</a>, and ‘bearish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">TCNNF</a> and&nbsp;<a href="https://stocktwits.com/symbol/IIPR">IIPR</a> as of the last reading.&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF (MSOS)</a>, which tracks U.S. cannabis companies exclusively, and the&nbsp;<a href="https://stocktwits.com/symbol/YOLO">AdvisorShares Pure Cannabis ETF (YOLO)</a>, which also tracks overseas companies and cannabis-adjacent businesses, rose 3.4% and 2.7%, respectively.<h2 class="st-heading-2">CMS Initaitive</h2>The rally came after Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-26/medicare-to-test-making-cbd-treatment-available-for-seniors">reported</a> that the Centers for Medicare &amp; Medicaid Services (CMS) is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;Details of the proposed program aren’t available, but an early version of the plan focused on seniors in oncology and palliative care settings, according to a summary viewed by the news agency.Unnamed sources told Bloomberg that Howard Kessler, a payments financier who has advocated for expanded CBD access, met with Health and Human Services Secretary Robert F. Kennedy Jr. about the issue last month<h2 class="st-heading-2">A Trump Boost?</h2>The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. Hemp-derived cannabidiol (CBD) could "revolutionize senior healthcare" by slowing disease progression and serving as an alternative to prescription drugs, Trump had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-cannabis-stocks-lose-high-premarket-after-surge-triggered-by-trumps-post/chDDTJ9R3BB">said</a> in a video post in September.The previous month, Trump said his administration was weighing a move to reclassify marijuana as a less dangerous drug under federal law.That said, doubts over cannabis efficacy in healthcare remain. A&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836267">recent study</a> funded by the Food and Drug Administration suggested that prolonged use of CBD may cause liver toxicity, while other research suggests it can interfere with other medications, harm male reproductive health, and pose potential risks to children and pregnant women.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/holiday-shopping-could-soar-to-a-record-1-trillion-this-year-with-online-spending-blasting-to-new-highs/cL5eLqVREW6">Holiday Shopping Could Soar To A Record $1 Trillion This Year, With Online Spending Blasting To New Highs</a>

Tilray, IIPR, Trulieve, Other Cannabis Stocks Rally On Report Of Government Considering Adding CBD Treatment For Medicare Patients  

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. 

The Zacks Analyst Blog Highlights MSOS, CNBS, WEED, MJ and YOLO

Zacks Analyst Blog highlights MSOS, CNBS, WEED, MJ, and YOLO as marijuana ETFs soar over 100% in three months on U.S. legalization hopes and investor optimism.

From Loss to Lift-Off: Marijuana ETFs Rebound on Legalization Prospects 

Marijuana ETFs, such as WEED, MSOS, and CNBS, are rebounding as hopes for rescheduling boost investor optimism. 

YOLO
AdvisorShares Pure Cannabis ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest YOLO News

YOLOAdvisorShares Pure Cannabis ETF